Dossier
Galderma
Coverage of Galderma in the Nexus archive.
- Botox maker Galderma sees early boost from 'Ozempic face' trend as GLP-1 use climbs, CEO says
Galderma, a Botox maker, is experiencing an early boost from the 'Ozempic face' trend linked to increased GLP-1 use. The company's CEO expects rising demand for treatments addressing facial volume loss associated with this trend.
- Galderma Slumps After FDA Turns Down Botox Rival Relfydess
Galderma's stock declined following the FDA's rejection of Relfydess, a Botox competitor. The decision negatively impacted the company's market performance.